Abstract:Abstract Background: The oxaliplatin-based chemotherapy has revealed an encouraging therapeutic efficacy for advanced hepatocellular carcinoma patients. However, the development of resistance limits its clinical utilization. In addition, the chemotherapy resistance in HCC is usually accompanied with other malignant phenotypes, such as cell proliferation and metastasis, which together result in poor prognosis of HCC patients. Therefore, efforts should be made to explore potential regulators which fuel multiple events of HCC progression.Methods: The qRT-PCR, western blot, immunohistochemistry and immunofluorescence were performed to measure mRNA and protein expression. MTT assay, colony formation and Transwell assay were performed to evaluate cell proliferation and metastasis. Flow cytometry was performed to test cell apoptosis. Alkaline Comet assay was performed to measure DNA lesions. Transmission electron microscope analysis provided potent testimony of autophagy. The role of HN1 on the malignant phenotypes of hepatoma carcinoma was demonstrated in vitro and in vivo.Results: The immunohistochemistry analysis of HCC patient tissues revealed that the expression of HN1 was higher in HCC tissues compared to adjacent tissues and was associated with worse prognosis. In vitro, HN1 knockdown inhibited proliferation and metastasis of HCC cells, whereas HN1 overexpression promoted their proliferation and metastasis. In addition, we found that HN1 knockdown sensitized HCC cells to oxaliplatin, which is companied with deteriorated DNA damage and increased cell apoptosis in oxaliplatin-treated HCC cells. In vivo, HN1 knockdown inhibited the tumor growth and metastasis, and promoted the anti-cancer efficiency of oxaliplatin. Mechanically, HN1 prevented HMGB1 from ubiquitination and degradation via autophagy-lysosome pathway, which is related to its interaction with TRIM28, and overexpression of HMGB1 can restore the malignant phenotypes of HN1 knockdown in HCC cells. Furthermore, we found that HN1 can regulate cellular autophagy via HMGB1, which is important to tumor-promoting effect of HN1.Conclusions: In conclusion, we systemically revealed the multiple functions of HN1 in HCC progression and the underlying molecular mechanism, which indicated that HN1 could be a promising therapeutic target for HCC treatment.

NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma

MNS1 Promotes Hepatocarcinogenesis and Metastasis Via Activating PI3K/AKT by Translocating Β‐catenin and Predicts Poor Prognosis

NOD2 Inhibits Tumorigenesis and Increases Chemosensitivity of Hepatocellular Carcinoma by Targeting AMPK Pathway.

NOD2 Inhibits Tumorigenesis and Increases Chemosensitivity of Hepatocellular Carcinoma by Targeting LKB1/AMPK/mTORC1 Axis

Activation of NOD1 on tumor-associated macrophages augments CD8 + T cell–mediated antitumor immunity in hepatocellular carcinoma

HN1 Promotes Proliferation, Metastasis and Attenuates the Chemosensitivity of HCC Cells to Oxaliplatin by Inhibiting Degradation of HMGB1 Through Interacting with TRIM28

Inhibition of the Wnt/β-catenin Signaling Pathway Improves the Anti-Tumor Effects of Sorafenib Against Hepatocellular Carcinoma.

PNO1 regulates autophagy and apoptosis of hepatocellular carcinoma via the MAPK signaling pathway

Inhibition of NPC1 suppresses cell proliferation and β-catenin signaling activation of liver cancer

Anti‐Proliferation Effect of Nodosin on Hepatocellular Carcinoma Cells Via The ERCC6L/PI3K/AKT/Axis

Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma

NOD-like Receptor X1 Functions As a Tumor Suppressor by Inhibiting Epithelial-Mesenchymal Transition and Inducing Aging in Hepatocellular Carcinoma Cells.

CNDP1 Suppresses the Malignant Behavior of Hepatoma Cell via Restricting PI3K-AKT-mTOR Activation

The HN1/HMGB1 Axis Promotes the Proliferation and Metastasis of Hepatocellular Carcinoma and Attenuates the Chemosensitivity to Oxaliplatin

The Rho GTPase Rnd1 Inhibits Epithelial–mesenchymal Transition in Hepatocellular Carcinoma and is a Favorable Anti-Metastasis Target

Tumor-Promoting Actions of HNRNP A1 in HCC Are Associated with Cell Cycle, Mitochondrial Dynamics, and Necroptosis

NAD(P)H: Quinone Oxidoreductase 1 Overexpression in Hepatocellular Carcinoma Potentiates Apoptosis Evasion Through Regulating Stabilization of X-linked Inhibitor of Apoptosis Protein.

Nod1-Dependent Control Of Tumor Growth

Notch1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma by Modulating the Cell Cycle, Mitochondrial Function, and Epithelial–mesenchymal Transition

SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway

Inhibition of NOTCH1 signaling in tumor-initiating cells overcomes chemoresistance and promotes apoptosis